Results 281 to 290 of about 48,696 (305)
Some of the next articles are maybe not open access.
Use of dabigatran with antiretrovirals
HIV Medicine, 2019ObjectivesTheoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral ...
J Perram, E O'Dwyer, C Holloway
openaire +3 more sources
Journal of Gastroenterology and Hepatology, 2020
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma +4 more
semanticscholar +1 more source
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma +4 more
semanticscholar +1 more source
Dabigatran: A Primer for Neurosurgeons
World Neurosurgery, 2013This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).Dabigatran has the advantage of providing rapid and steady anticoagulation without ...
Jennifer E. Fugate +3 more
openaire +3 more sources
Removal of Dabigatran by Hemodialysis
American Journal of Kidney Diseases, 2013Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
Don N. Chang +2 more
openaire +3 more sources
Drug Metabolism and Personalized Therapy, 2020
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev +13 more
semanticscholar +1 more source
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev +13 more
semanticscholar +1 more source
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke, 2020Supplemental Digital Content is available in the text. Background and Purpose— Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous ...
J. Beharry +8 more
semanticscholar +1 more source
Reversal of Dabigatran with Idarucizumab
Expert Review of Cardiovascular Therapy, 2016The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R. Sodha, Frank W. Sellke
openaire +3 more sources
American Journal of Health-System Pharmacy, 2011
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Steven R. Kayser +3 more
openaire +2 more sources
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Steven R. Kayser +3 more
openaire +2 more sources
Dabigatran-Induced Esophagitis
Clinical Gastroenterology and Hepatology, 2014We report 2 cases of drug-induced esophagitis associated with dabigatran, a new oral anticoagulant. Both patients were prescribed dabigatran at 110 mg twice daily for atrial fibrillation as an alternative to warfarin. The first case was a 70-year-old man who had been taking dabigatran for 14 days and was referred to our hospital because of retrosternal
Yoshihiro Hayashi +2 more
openaire +3 more sources
Dabigatran in Clinical Practice
Clinical Therapeutics, 2012Stroke and systemic thromboembolism remain critical causes of mortality and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. Randomized clinical data demonstrate dabigatran to be
Christopher R. Ellis +1 more
openaire +3 more sources